MCID: OVR105
MIFTS: 41

Ovarian Serous Carcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Carcinoma

MalaCards integrated aliases for Ovarian Serous Carcinoma:

Name: Ovarian Serous Carcinoma 12 15 17
Ovarian Serous Adenocarcinoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050933
UMLS 74 C1335177

Summaries for Ovarian Serous Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in the lining of the ovary and produces a serum-like fluid.

MalaCards based summary : Ovarian Serous Carcinoma, also known as ovarian serous adenocarcinoma, is related to breast cancer and primary peritoneal carcinoma. An important gene associated with Ovarian Serous Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and miRNA targets in ECM and membrane receptors. The drugs Trametinib and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and endothelial.

Related Diseases for Ovarian Serous Carcinoma

Diseases related to Ovarian Serous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 breast cancer 27.9 MIR10B MIR125A MIR141 MIR143 MIR145 MIR200A
2 primary peritoneal carcinoma 11.6
3 polymyositis 10.2 MIR21 MIR214
4 dermatomyositis 10.2 MIR21 MIR214
5 esophagus adenocarcinoma 10.2 MIR143 MIR145 MIR21
6 lymphoma, hodgkin, classic 10.1 MIR200A MIR20A MIR21
7 congestive heart failure 10.1 MIR21 MIR214 MIR23A
8 peritoneal mesothelioma 10.1
9 endometrioid ovary carcinoma 10.1
10 autism spectrum disorder 10.0 MIR21 MIR23A MIR93
11 muscular dystrophy, duchenne type 10.0 MIR21 MIR214 MIR29A
12 pancreatitis, hereditary 10.0 MIR10B MIR125A MIR99A
13 diffuse large b-cell lymphoma 10.0 MIR143 MIR145 MIR21 MIR99A
14 squamous cell carcinoma, head and neck 10.0 MIR141 MIR200A MIR21 MIR214
15 leukemia, chronic lymphocytic 2 9.9 MIR143 MIR145 MIR29A
16 brittle bone disorder 9.9
17 endodermal sinus tumor 9.9
18 papillary serous adenocarcinoma 9.9
19 papillary carcinoma 9.9
20 pancreatic ductal carcinoma 9.9
21 uterine corpus serous adenocarcinoma 9.9
22 inflammatory breast carcinoma 9.9
23 col1a1/2-related osteogenesis imperfecta 9.9
24 hypoxia 9.9
25 pancreatic ductal adenocarcinoma 9.8 MIR141 MIR143 MIR145 MIR21 MIR93
26 leukemia, acute lymphoblastic 9.8 MIR125A MIR21 MIR23A MIRLET7B
27 nonalcoholic fatty liver disease 9.7 MIR10B MIR200A MIR200C MIR21
28 psoriasis 9.7 MIR100 MIR141 MIR200A MIR20A MIR21
29 vascular disease 9.7 MIR125A MIR143 MIR145 MIR21 MIR214
30 primary biliary cirrhosis 9.7 MIR20A MIRLET7B
31 facioscapulohumeral muscular dystrophy 1 9.7 MIR21 MIR214 MIR29A MIRLET7B
32 cervical cancer 9.7 MIR143 MIR21 MIR214 MIRLET7B
33 leukemia, acute myeloid 9.6 MIR125A MIR21 MIR23A MIRLET7B
34 adamantinoma of long bones 9.6 MIR141 MIR200A MIR200C
35 bladder cancer 9.4 MIR100 MIR10B MIR143 MIR145 MIR21 MIR23A
36 neuroblastoma 9.3 MIR125A MIR29A MIR93 MIR99A MIRLET7B
37 melanoma 9.2 MIR100 MIR141 MIR200A MIR200C MIRLET7B
38 oral squamous cell carcinoma 9.2 MIR100 MIR143 MIR200C MIR21 MIR23A MIR29A
39 kidney cancer 9.2 MIR141 MIR200C MIR20A MIR21 MIR214 MIR29A
40 endometriosis 9.1 MIR100 MIR125A MIR141 MIR143 MIR145 MIR200A
41 pancreatic cancer 8.9 MIR100 MIR10B MIR125A MIR143 MIR20A MIR21
42 gastric cancer 8.9 MIR141 MIR143 MIR145 MIR200C MIR20A MIR21
43 hepatocellular carcinoma 8.0 MIR125A MIR141 MIR143 MIR145 MIR200A MIR20A
44 ovarian cancer 8.0 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
45 prostate cancer 7.9 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
46 colorectal cancer 7.6 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
47 lung cancer 7.4 MIR100 MIR125A MIR141 MIR143 MIR145 MIR200A

Graphical network of the top 20 diseases related to Ovarian Serous Carcinoma:



Diseases related to Ovarian Serous Carcinoma

Symptoms & Phenotypes for Ovarian Serous Carcinoma

Drugs & Therapeutics for Ovarian Serous Carcinoma

Drugs for Ovarian Serous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
2
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3 123948-87-8, 119413-54-6 60700
3
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
4
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
5
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
6
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
7
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
8
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
9
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
10
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
11
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 38904 10339178 498142
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
15
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
16
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
17
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
18
SB-649868 Experimental, Investigational Phase 2, Phase 3,Phase 1 110-16-7, 110-17-8 444972
19
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
20 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
21 Chelating Agents Phase 2, Phase 3
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
23 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
24 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
25 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
26 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
27 Calcium, Dietary Phase 2, Phase 3
28 Estrogens Phase 2, Phase 3
29 Anticoagulants Phase 2, Phase 3
30 Estrogen Antagonists Phase 2, Phase 3
31 Aromatase Inhibitors Phase 2, Phase 3
32 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
33 Antineoplastic Agents, Hormonal Phase 2, Phase 3
34 Bone Density Conservation Agents Phase 2, Phase 3
35 Hormones Phase 2, Phase 3
36 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3
37 Steroid Synthesis Inhibitors Phase 2, Phase 3
38 Estrogen Receptor Antagonists Phase 2, Phase 3
39 Citrate Phase 2, Phase 3
40 Hormone Antagonists Phase 2, Phase 3
41 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
42 Selective Estrogen Receptor Modulators Phase 2, Phase 3
43 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
44 Estrogen Receptor Modulators Phase 2, Phase 3
45 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
46 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
47 Antibodies Phase 3,Phase 2,Phase 1
48 Immunoglobulins Phase 3,Phase 2,Phase 1
49 Immunologic Factors Phase 3,Phase 2,Phase 1
50 Immunoglobulin G Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
2 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
3 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
4 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
5 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
8 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
10 Ribociclib and Letrozole Treatment in Ovarian Cancer Recruiting NCT03673124 Phase 2 Ribociclib;Letrozole
11 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Recruiting NCT02953457 Phase 2 Olaparib
12 Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn NCT02756130 Phase 1, Phase 2 Birinapant;Carboplatin
13 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
14 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02923739 Phase 2 Paclitaxel
15 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
16 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
17 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
18 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
19 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
20 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
21 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2 ATR Kinase Inhibitor M6620;Carboplatin;Gemcitabine Hydrochloride
22 Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03587311 Phase 2 Paclitaxel
23 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
24 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
25 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Recruiting NCT03608618 Phase 1
26 To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Completed NCT02179970 Phase 1 Plerixafor
27 Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn NCT02627430 Phase 1 Hsp90 Inhibitor AT13387;Talazoparib
28 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
29 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
30 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
31 Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Not yet recruiting NCT03586661 Phase 1 Copanlisib;Niraparib
32 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Recruiting NCT02898207 Phase 1 Olaparib;Onalespib
33 Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System Completed NCT00837993
34 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Completed NCT02016833
35 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
36 Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer Recruiting NCT03606486 Not Applicable
37 Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02316834 Early Phase 1 BMN 673

Search NIH Clinical Center for Ovarian Serous Carcinoma

Genetic Tests for Ovarian Serous Carcinoma

Anatomical Context for Ovarian Serous Carcinoma

MalaCards organs/tissues related to Ovarian Serous Carcinoma:

42
Ovary, Breast, Endothelial, Bone, Lymph Node, Lung, Skin

Publications for Ovarian Serous Carcinoma

Articles related to Ovarian Serous Carcinoma:

(show top 50) (show all 127)
# Title Authors Year
1
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers. ( 30857227 )
2019
2
Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma. ( 30915911 )
2019
3
TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma. ( 29435041 )
2018
4
Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma. ( 29928365 )
2018
5
Decreased Eph receptora89A1 expression is related to grade in ovarian serous carcinoma. ( 29393455 )
2018
6
Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. ( 29668586 )
2018
7
Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis. ( 30356023 )
2018
8
Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma. ( 30383611 )
2018
9
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. ( 28959512 )
2017
10
ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. ( 28178720 )
2017
11
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
12
High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. ( 29262533 )
2017
13
Aldehyde dehydrogenase 1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. ( 28851663 )
2017
14
A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. ( 27836204 )
2017
15
Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. ( 28599499 )
2017
16
miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. ( 29079174 )
2017
17
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma. ( 28454318 )
2017
18
Two independent incidences of skin metastases in the umbilicus and abdominal wall in ovarian serous adenocarcinoma: A case report and review of the literature. ( 29245346 )
2017
19
Metastatic Ovarian Serous Carcinoma of the Breast. ( 27943469 )
2016
20
Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages. ( 27275818 )
2016
21
B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Cases. ( 27349304 )
2016
22
Immunostaining Study on the Expression of NF-I_B, ER, and PR in Ovarian Serous Carcinoma. ( 27171541 )
2016
23
EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. ( 27887627 )
2016
24
Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" Int J Gynecol Cancer 2015;25: 1201-1207. ( 26807559 )
2016
25
Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. ( 27802199 )
2016
26
Widespread cutaneous metastasis from ovarian serous adenocarcinoma. ( 27617723 )
2016
27
PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. ( 26504072 )
2015
28
Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. ( 26468391 )
2015
29
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. ( 25455994 )
2015
30
Expression pattern of RAGE and IGF-1 in the human fetal ovary and ovarian serous carcinoma. ( 25724694 )
2015
31
Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. ( 26250968 )
2015
32
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. ( 26232338 )
2015
33
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma? ( 26035124 )
2015
34
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. ( 25889687 )
2015
35
Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report. ( 26189267 )
2015
36
Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. ( 26550417 )
2015
37
Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. ( 24888238 )
2014
38
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. ( 24814803 )
2014
39
Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis. ( 24348821 )
2014
40
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. ( 24756216 )
2014
41
Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. ( 24262874 )
2014
42
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. ( 24926085 )
2014
43
Primary ovarian serous adenocarcinoma with ipsilateral axillary lymph node metastasis: a case report. ( 25419072 )
2014
44
Late isolated central nervous system relapse from ovarian serous adenocarcinoma: a case report and literature review. ( 25506007 )
2014
45
Migfilin, I+-parvin and I^-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. ( 23099104 )
2013
46
Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern. ( 23368871 )
2013
47
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. ( 23656974 )
2013
48
miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. ( 23722670 )
2013
49
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. ( 24060004 )
2013
50
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. ( 23438671 )
2013

Variations for Ovarian Serous Carcinoma

Copy number variations for Ovarian Serous Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 109396 17 25800000 31800000 Deletion NF1 Ovarian serous carcinoma

Expression for Ovarian Serous Carcinoma

Search GEO for disease gene expression data for Ovarian Serous Carcinoma.

Pathways for Ovarian Serous Carcinoma

Pathways related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
2 10.97 MIR141 MIR200A MIR200C
3 10.96 MIR100 MIR145 MIR23A MIR93
4 10.7 MIR29A MIRLET7B

GO Terms for Ovarian Serous Carcinoma

Cellular components related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 MIR100 MIR10B MIR125A MIR141 MIR143 MIR20A
2 micro-ribonucleoprotein complex GO:0035068 9.5 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145

Biological processes related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 MIR21 MIR23A MIRLET7B
2 positive regulation of protein kinase B signaling GO:0051897 9.8 MIR143 MIR21 MIR29A
3 negative regulation of cell migration GO:0030336 9.77 MIR21 MIR214 MIR29A
4 negative regulation of protein kinase B signaling GO:0051898 9.72 MIR145 MIR20A MIR29A
5 negative regulation of gene expression GO:0010629 9.72 MIR125A MIR20A MIR21 MIR214 MIR29A
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 MIR20A MIR21 MIR214
7 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 MIR143 MIR200A
8 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.65 MIR214 MIR29A
9 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.64 MIR10B MIR23A
10 activation of protein kinase B activity GO:0032148 9.64 MIR143 MIR21
11 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.63 MIR20A MIR23A
12 negative regulation of smooth muscle cell proliferation GO:0048662 9.63 MIR143 MIR145
13 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 MIR145 MIR20A MIR21
14 negative regulation of stress fiber assembly GO:0051497 9.62 MIR20A MIR21
15 positive regulation of vascular endothelial cell proliferation GO:1905564 9.61 MIR21 MIR29A
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR21 MIR214
17 negative regulation of cardiac muscle hypertrophy GO:0010614 9.59 MIR145 MIR21
18 regulation of smooth muscle contraction GO:0006940 9.58 MIR143 MIR145
19 positive regulation of endothelial cell differentiation GO:0045603 9.58 MIR200C MIR21
20 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR143 MIR20A MIR21
21 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR20A MIR214
22 angiotensin-activated signaling pathway GO:0038166 9.56 MIR143 MIR145
23 miRNA mediated inhibition of translation GO:0035278 9.56 MIR145 MIR20A MIR21 MIR29A
24 positive regulation of angiogenesis GO:0045766 9.55 MIR143 MIR20A MIR21 MIR29A MIRLET7B
25 aorta smooth muscle tissue morphogenesis GO:0060414 9.54 MIR143 MIR145
26 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.54 MIR10B MIR23A MIRLET7B
27 gene silencing by miRNA GO:0035195 9.53 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
28 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.51 MIR21 MIRLET7B
29 regulation of phenotypic switching GO:1900239 9.49 MIR143 MIR145
30 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.48 MIR143 MIR20A
31 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR143 MIR145
32 negative regulation of angiogenesis GO:0016525 9.43 MIR125A MIR143 MIR145 MIR21 MIR214 MIR29A

Molecular functions related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR10B MIR125A MIR141 MIR143 MIR145 MIR200A
2 RNA polymerase II complex binding GO:0000993 9.13 MIR125A MIR145 MIR20A

Sources for Ovarian Serous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....